$CALC

CalciMedica (NASDAQ: CALC) faces Nasdaq market value and $1 bid price breaches

CalciMedica (NASDAQ: CALC) has received two notices from Nasdaq for non-compliance, specifically for its market value of listed securities falling below $35 million and its common stock trading below the $1 minimum bid price for 30 consecutive business days. The company has 180 calendar days for each deficiency, until September 9, 2026, for market value and September 14, 2026, for bid price, to regain compliance through various alternatives, including a possible reverse stock split. Failure to do so could result in delisting from the Nasdaq Capital Market.

Original reporting
Published Mar 19, 2026, 2:39 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Mar 19, 2026, 3:00 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefFinancial news
Primary signal
$CALC
Bearish
medium confidence
Mentioned
$CALC
alphai data visualization · based on Stock Titan
Decision brief

The 30-second read

$CALCBearishMed
01

Why it matters

Failure to regain compliance could lead to delisting, negatively impacting shareholders and liquidity.

02

Market read

The news is highly relevant for investors holding or considering CalciMedica shares, especially in the biotech sector.

03

What to watch

Potential for a strategic reverse split or other measures to restore compliance and stabilize the stock.

Timing: Immediate to short-term

Background

CalciMedica has been notified by Nasdaq for non-compliance related to market value and bid price requirements, risking delisting if issues are not resolved within specified deadlines.

Company-level read

Ticker impact

$CALCBearishMedium confidence
Context

High relevance due to direct impact on company's listing status and market value.

Expected impact

Short-term decline expected if delisting fears intensify; potential rebound if the company successfully regains compliance.

Evidence & confidence

The breach of Nasdaq listing requirements introduces uncertainty, likely causing short-term negative price movement. The outcome depends on the company's corrective measures.

Market effects

Potential negative sentiment for biotech and life sciences sectors due to regulatory and compliance concerns.

Limited regional impact; primarily affects Nasdaq-listed biotech firms.

Low; specific to Nasdaq-listed company.

Counterpoint

The company might successfully address the compliance issues, leading to a rebound in stock price.

Key entities

  • CalciMedica

    A biotech firm listed on NASDAQ facing compliance issues.

Related articles

$ETNMed

Eaton Gains on $7-Million Contract

Eaton (NYSE:ETN) said the U.S. Air Force Research Laboratory awarded it a $7 million, 24-month contract to use quantum computing, machine learning, and advanced visualization to improve power grid resilience and protection. The work, with Infleqtion and Penn State, targets detection and response to multiple concurrent physical and cyber threats, addressing NERC N-2 contingency requirements.

$XOMMed

ExxonMobil awards McDermott engineering work for Rovuma LNG

ExxonMobil Moçambique Limitada issued McDermott Energy Solutions (UK) a letter of intent for limited engineering and procurement work on Rovuma LNG Phase 1 midstream development. The award supports planning ahead of a final investment decision expected in 2026. Rovuma LNG targets 12 modular trains totaling 18.6 mtpa, with start-up in 2031. ExxonMobil says the 30-year project could generate about $150B in revenues for Mozambique’s government.

$ESLTMed

Serbia to open joint UAV factory with Elbit in September

Serbia President Aleksandar Vucic said Serbia will open a joint UAV factory with Elbit Systems, with inauguration expected Sept 15-20. Elbit will hold 51% and Serbia’s state arms firm SDPR 49%. The factory relates to a five-year contract covering precision rockets and unmanned systems, plus ISTAR, digitization and upgrades.

$NOCMed

The Pentagon is urging defense contractors to urgently ramp up weapons production – WP

The U.S. Department of Defense, according to The Washington Post, asked defense contractors to submit within 21 days production and delivery schedules for critical systems, citing depleted stockpiles. CSIS estimates cite heavy early use of missiles and falling Patriot and THAAD inventories. The Pentagon is working with Northrop Grumman and Lockheed Martin, including a $58.6B deal to triple PAC-3 output by 2030, pending a stalled $1.15T defense budget.

$LMTMed

Pentagon pushes military contractors to accelerate production amid shortages after war on Iran

The Pentagon ordered US defense contractors to submit within 21 days plans to accelerate production of missiles and interceptors amid shortages after the first month of strikes against Iran. It cited depleted Patriot and THAAD inventories and said framework agreements with Lockheed Martin and Northrop Grumman target PAC-3 and THAAD output. Lockheed Martin received a contract up to $58.6B to triple PAC-3 production by 2030.

$NOCMed

WP: Pentagon asks defense companies to urgently ramp up weapons production

The Pentagon, via Deputy Secretary Steve Feinberg, urged U.S. defense firms to accelerate weapons output, especially ammunition, and asked executives to submit production and delivery plans within 21 days, according to The Washington Post. CSIS data cited Patriot and THAAD stockpiles falling sharply. The article notes talks with Northrop Grumman and Lockheed Martin and a Lockheed contract up to $58.6B to triple PAC-3 output by 2030.